AXSM Axsome Therapeutics
- 77.350
- +1.420+1.87%
Axsome Therapeutics News
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Axsome Therapeutics, Inc., a biopharmaceutica
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Axsome Therapeutics Is Maintained at Buy by Mizuho
Axsome Therapeutics Is Maintained at Buy by Mizuho
Axsome Therapeutics Price Target Cut to $106.00/Share From $109.00 by Mizuho
Axsome Therapeutics Price Target Cut to $106.00/Share From $109.00 by Mizuho
Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $106
Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $109 to $106.
Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating
Axsome Therapeutics (AXSM) has an average rating of buy and price targets ranging from $97 to $190, according to analysts polled by Capital IQ.
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)
Axsome Therapeutics to Present at Upcoming Investor Conferences
PDF Version NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of cent
Buy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trials
Axsome Therapeutics Price Target Cut to $125.00/Share From $127.00 by Citigroup
Axsome Therapeutics Price Target Cut to $125.00/Share From $127.00 by Citigroup
Axsome Therapeutics Is Maintained at Buy by Citigroup
Axsome Therapeutics Is Maintained at Buy by Citigroup
Citi: Maintains Axsome Therapeutics (AXSM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $127.00 to $125.00.
Citi: Maintains Axsome Therapeutics (AXSM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $127.00 to $125.00.
Citigroup Maintains Buy on Axsome Therapeutics, Lowers Price Target to $125
Citigroup analyst David Hoang maintains Axsome Therapeutics with a Buy and lowers the price target from $127 to $125.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed on Axsome Therapeutics Due to Strong Auvelity Sales and Promising Alzheimer's Treatment Pipeline
Axsome Therapeutics (AXSM) Gets a Buy From RBC Capital
Axsome Therapeutics Price Target Raised to $112.00/Share From $108.00 by Baird
Axsome Therapeutics Price Target Raised to $112.00/Share From $108.00 by Baird
Axsome Therapeutics Is Maintained at Outperform by Baird
Axsome Therapeutics Is Maintained at Outperform by Baird
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $190 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics with a Buy and maintains $190 price target.
Axsome Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 150.2% HC Wainwright & Co. → $190 Reiterates Buy → Buy 04/29/2024 51.44% Morgan Stanley $90 → $
Analysis
Price Target
No Data
